Assoc. Prof. Dr. Murat Ayhan is a medical oncologist at Liv Hospital Vadistanbul in Istanbul, Turkey, specializing in the medical treatment of cancer.
He graduated from Dicle University Faculty of Medicine in 2007, completed his Internal Medicine residency at Istanbul Medeniyet University Göztepe Training and Research Hospital in 2014, and completed his subspecialty training in Medical Oncology at Kartal Dr. Lütfi Kırdar City Hospital in 2021. He was awarded the academic title of Associate Professor of Medical Oncology in 2023.
His clinical interests include breast cancer, lung cancer, colorectal cancer, gynecological cancers, and genitourinary malignancies.
His practice also encompasses systemic cancer treatments, including chemotherapy, targeted therapy, and immunotherapy, as well as molecular oncology approaches that help guide individualized treatment decisions. He has contributed to clinical research investigating cancer treatment outcomes, systemic therapies, and oncology-related complications.
Education and Academic Qualifications
- Kızıltepe Anatolian High School, 2001
- Medical Degree from the Faculty of Medicine, Dicle University, 2007
- Residency in Internal Medicine at Göztepe Training and Research Hospital, Istanbul Medeniyet University, 2014
- Fellowship in Medical Oncology at Kartal Dr. Lutfi Kirdar City Hospital, 2021
- Earned the title of Associate Professor of Medical Oncology, 2023
Areas of Interest
-
Breast cancer treatment in Turkey.
-
Medical treatment of breast cancer.
-
Advanced breast cancer treatment.
-
Lung cancer treatment in Turkey.
-
Non-small cell lung cancer treatment.
-
Colon cancer treatment in Turkey.
-
Rectal cancer treatment.
-
Metastatic colorectal cancer treatment.
-
Gynecological cancer treatment in Turkey.
-
Medical treatment of ovarian cancer.
-
Genitourinary cancer treatment.
-
Medical treatment of prostate cancer.
-
Bladder cancer treatment.
-
Cancer chemotherapy in Turkey.
-
Cancer immunotherapy.
-
Targeted cancer therapy in Turkey.
-
Molecular oncology.
-
Systemic treatment of advanced and metastatic cancers.